RT Journal Article
T1 Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
A1 Casanova, Ciro
A1 Celli, Bartolome R.
A1 de-Torres, Juan P.
A1 Martinez-Gonzalez, Cristina
A1 Cosio, Borja G.
A1 Pinto-Plata, Victor
A1 de Lucas-Ramos, Pilar
A1 Divo, Miguel
A1 Fuster, Antonia
A1 Peces-Barba, German
A1 Calle-Rubio, Myriam
A1 Solanes, Ingrid
A1 Aguero, Ramon
A1 Feu-Collado, Nuria
A1 Alfageme, Inmaculada
A1 De Diego, Alfredo
A1 Romero, Amparo
A1 Balcells, Eva
A1 Llunell, Antonia
A1 Galdiz, Juan B.
A1 Marin, Margarita
A1 Moreno, Amalia
A1 Cabrera, Carlos
A1 Golpe, Rafael
A1 Lacarcel, Celia
A1 Soriano, Joan B.
A1 Luis Lopez-Campos, Jose
A1 Soler-Cataluna, Juan J.
A1 Marin, Jose M.
K1 Obstructive pulmonary-disease
K1 Clinical characteristics
K1 Inhaled corticosteroids
K1 Exacerbations
K1 Asthma
K1 Fluticasone
K1 Guidelines
K1 Biomarker
K1 Efficacy
K1 Dyspnea
AB The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (>= 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.
PB European Respiratory Society
SN 0903-1936
YR 2017
FD 2017-07-27
LK http://hdl.handle.net/10668/19115
UL http://hdl.handle.net/10668/19115
LA en
NO Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017 Nov 22;50(5):1701162
DS RISalud
RD Apr 7, 2025